2022-RA-985-ESGO Predictors of recurrence in adult granulosa cell type ovarian cancer: a retrospective cohort study. (20th October 2022)

• Record Type: Journal Article
• Authors: Huddart, Daniel; Abdelbar, Ahmed; Sayasneh, Ahmad
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A288
• Page End: A288
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.612
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: Adult granulosa cell type (AGCT) ovarian cancer represents up to 5% of ovarian cancer. Although outcomes are generally favourable, a small group of patients experience disease recurrence. This typically occurs 5 – 10 years after initial treatment and has a poor prognosis. The peritoneal cancer index (PCI) score is used to predict prognosis in patients with epithelial ovarian cancer but has not been validated for AGCT ovarian cancer. This study aims to investigate predictors of recurrence (including PCI score) in patients with AGCT at a London Tertiary hospital. Methodology: This retrospective cohort study analysed the data of all patients with confirmed AGCT ovarian cancer treated at Guy's and St Thomas' NHS Foundation Trust between January 2001 and November 2021. Data were extracted from patient notes including age and FIGO stage at diagnosis, alongside PCI score at both initial surgery and subsequent surgeries for disease recurrence. All deaths were noted, including deaths related to ovarian cancer Results: 45 patients were identified, of which 9(20%) experienced disease recurrence. 4 of these patients experienced disease recurrence three times. The mean age at diagnosis of patients without disease recurrence was 47.19 (95%CI 42.20, 52.20) and mean PCI score 0.06 (95%CI -0.046, 0.166), compared to 57.0 (95%CI 46.20, 67.80) and 1.78 (95%CI 0.07, 3.49) for patients with disease recurrence. Table 1 provides a breakdown of the FIGO staging in each group. There were 0 ovarian cancer related deaths in patients without recurrence, compared to 4(40%) in patients with recurrence. Conclusion: Disease recurrence was more likely in patients with FIGO stage greater than 1a. However, one case of recurrence was noted in a patient with 1a disease. PCI score was higher in patients that later experienced recurrence, although not statistically significant. Future research should examine if PCI score can predict recurrence in larger patient populations.